Double maintains 1 strategies that include ALXO - ALX Oncology Holdings, Inc.
Yahoo
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the
Yahoo
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20Company will not pursue U.S. registrational
Yahoo
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. A
Yahoo
Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.
Yahoo
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination generated complete responses (CR) in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R2 alone - Phase 2 portion of trial in patients with previously untreat
Yahoo
In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent safety data in prior clinical trials SOUTH SAN FRANCISCO, April 25, 2025 (GLOB
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -24.93% | $361.41M | 1.43% |
VIXY | -18.01% | $109.64M | 0.85% |
TAIL | -17.69% | $140.49M | 0.59% |
KRBN | -15.71% | $160.09M | 0.85% |
IBTF | -14.19% | $2.12B | 0.07% |
XBIL | -12.06% | $782.40M | 0.15% |
UTWO | -11.11% | $387.71M | 0.15% |
STPZ | -10.89% | $446.46M | 0.2% |
SCHO | -10.75% | $10.87B | 0.03% |
IVOL | -10.65% | $353.94M | 1.02% |
BUXX | -10.46% | $284.43M | 0.25% |
SPTS | -10.38% | $5.76B | 0.03% |
IDU | -9.91% | $1.42B | 0.39% |
IBTH | -9.51% | $1.53B | 0.07% |
FLDR | -9.37% | $841.44M | 0.15% |
XLU | -9.25% | $18.46B | 0.09% |
VPU | -9.19% | $6.75B | 0.09% |
BIL | -9.15% | $45.95B | 0.1356% |
FUTY | -8.95% | $1.76B | 0.084% |
IBTJ | -8.89% | $658.04M | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MX | <0.01% | $142.81M | -22.66% | 0.00% |
MESO | <0.01% | $1.53B | +70.23% | 0.00% |
KMI | 0.01% | $62.22B | +42.86% | 4.11% |
TAP | 0.02% | $11.38B | -2.05% | 3.16% |
SAVA | 0.03% | $99.03M | -90.49% | 0.00% |
CCI | -0.05% | $43.88B | -3.12% | 6.19% |
UNH | 0.05% | $248.87B | -47.37% | 3.06% |
FTS | 0.06% | $23.72B | +15.88% | 3.70% |
ESGR | 0.06% | $4.98B | +8.17% | 0.00% |
INVH | -0.08% | $20.86B | -3.35% | 3.35% |
GHI | -0.14% | $272.58M | -23.91% | 12.67% |
VIV | 0.15% | $16.11B | +13.49% | 0.00% |
AXON | 0.15% | $56.71B | +150.79% | 0.00% |
EZPW | -0.16% | $753.14M | +34.74% | 0.00% |
JNJ | -0.16% | $360.54B | -3.03% | 3.32% |
TASK | -0.16% | $1.48B | +9.64% | 0.00% |
FDUS | 0.16% | - | - | 8.41% |
ZCMD | 0.17% | $32.45M | -11.38% | 0.00% |
AMBC | 0.17% | $366.78M | -56.23% | 0.00% |
MMS | 0.17% | $4.24B | -13.54% | 1.59% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 33.14% | $40.65M | 0.5% |
IWC | 31.26% | $766.88M | 0.6% |
KJUL | 27.44% | $113.35M | 0.79% |
IWN | 27.35% | $11.10B | 0.24% |
ARKG | 27.20% | $944.78M | 0.75% |
BSVO | 27.18% | $1.40B | 0.47% |
IWM | 27.02% | $63.95B | 0.19% |
GSSC | 26.89% | $538.65M | 0.2% |
VTWO | 26.88% | $12.07B | 0.07% |
IBB | 26.83% | $5.22B | 0.45% |
SNSR | 26.71% | $223.26M | 0.68% |
KRE | 26.56% | $3.59B | 0.35% |
EES | 26.38% | $588.44M | 0.38% |
PRFZ | 26.35% | $2.33B | 0.34% |
XHB | 26.34% | $1.26B | 0.35% |
KBE | 26.28% | $1.50B | 0.35% |
SCHA | 26.00% | $16.91B | 0.04% |
DFSV | 25.80% | $4.63B | 0.3% |
IWO | 25.73% | $11.36B | 0.24% |
SDVY | 25.65% | $8.10B | 0.59% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XLP | <0.01% | $15.53B | 0.09% |
VTC | -<0.01% | $1.18B | 0.03% |
CGSD | 0.01% | $1.19B | 0.25% |
BGRN | -0.03% | $392.42M | 0.2% |
GIGB | 0.09% | $681.30M | 0.08% |
SPIP | 0.09% | $984.63M | 0.12% |
JPIB | 0.09% | $712.80M | 0.5% |
USFR | -0.13% | $18.91B | 0.15% |
TLTW | -0.13% | $1.03B | 0.35% |
EMLP | -0.15% | $3.18B | 0.96% |
SPBO | -0.18% | $1.54B | 0.03% |
IBDX | -0.21% | $1.05B | 0.1% |
LQD | 0.29% | $29.04B | 0.14% |
IBDZ | 0.29% | $324.49M | 0.1% |
CMBS | 0.32% | $427.55M | 0.25% |
VCEB | -0.33% | $829.73M | 0.12% |
CORP | -0.36% | $1.35B | 0.23% |
UGA | -0.43% | $73.47M | 0.97% |
CTA | 0.43% | $1.05B | 0.76% |
BSSX | -0.43% | $75.11M | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SO | -17.70% | $96.04B | +10.08% | 3.29% |
ED | -17.55% | $36.75B | +5.26% | 3.28% |
WEC | -16.39% | $33.48B | +22.69% | 3.29% |
CNP | -15.84% | $24.30B | +24.35% | 2.82% |
K | -14.73% | $28.49B | +32.17% | 2.77% |
DUK | -14.24% | $90.12B | +12.74% | 3.61% |
CHRW | -13.80% | $11.72B | +18.76% | 2.46% |
CALM | -13.69% | $5.17B | +66.43% | 6.96% |
DOGZ | -13.54% | $231.95M | +120.05% | 0.00% |
EXC | -13.39% | $43.84B | +12.45% | 3.59% |
AEE | -13.25% | $26.17B | +29.27% | 2.81% |
CL | -13.18% | $72.64B | -5.18% | 2.25% |
CPB | -13.08% | $10.42B | -25.16% | 4.36% |
COR | -12.87% | $55.43B | +28.90% | 0.56% |
VSTA | -12.51% | $326.82M | +11.64% | 0.00% |
FE | -12.46% | $24.49B | +5.52% | 4.06% |
PRT | -11.93% | $46.96M | +0.80% | 11.43% |
CMS | -11.77% | $21.21B | +12.27% | 2.97% |
CWAN | -11.77% | $6.50B | +23.76% | 0.00% |
CTRE | -11.70% | $5.49B | +15.16% | 4.19% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
COHU | 36.12% | $829.14M | -40.03% | 0.00% |
BAND | 35.86% | $434.54M | -34.29% | 0.00% |
CRBU | 34.20% | $78.11M | -76.60% | 0.00% |
MGNX | 33.21% | $97.16M | -69.92% | 0.00% |
WCC | 33.20% | $8.36B | -5.88% | 0.98% |
MRNA | 33.05% | $9.15B | -82.18% | 0.00% |
AME | 32.95% | $41.61B | +7.33% | 0.64% |
LAB | 32.40% | $398.81M | -58.00% | 0.00% |
TXG | 32.13% | $1.15B | -64.05% | 0.00% |
CGNX | 31.98% | $5.31B | -33.45% | 1.24% |
RLGT | 31.35% | $292.29M | +16.76% | 0.00% |
PAX | 31.18% | $1.95B | -4.03% | 6.16% |
ALLO | 30.92% | $238.42M | -63.79% | 0.00% |
NBHC | 30.79% | $1.46B | +6.02% | 2.98% |
IR | 30.63% | $33.49B | -9.19% | 0.12% |
ABCL | 30.49% | $602.94M | -46.56% | 0.00% |
TEX | 30.37% | $3.08B | -22.26% | 1.44% |
VNT | 30.23% | $5.45B | -8.27% | 0.27% |
NVEC | 30.07% | $343.58M | -7.59% | 4.22% |
ECVT | 30.03% | $884.03M | -22.21% | 0.00% |
Current Value
$0.441 Year Return
Current Value
$0.441 Year Return